Community

Advertising Opportunities

 Biotechnology Europe Programs

 Resources

Biotechnology Europe Community

Feedback

Contact

Biotechnology Europe Advantages

Advertising Opportunities on Biotechnology Europe

Sponsorship Opportunities on Biotechnology Europe

 

Post a Job on Biotechnology Europe

Post a Company Profile on Biotechnology Europe

Post a News on Biotechnology Europe

Post an Event on Biotechnology Europe

Post a Product on Biotechnology Europe

Post a Publication on Biotechnology Europe

Post a Technology on Biotechnology Europe

Post a Resume on Biotechnology Europe  

Terms of Business

Imprint

Privacy Policy

FAQ

Subscribe Newsletter

 

BIOTECHNOLOGY EUROPE-NETHERLANDS

OUT LICENSING

   



 

   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
 
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
 
 
 

Market Sectors (s)

Transdermal drug delivery - Medical devices

Type of opportunity

Product and/or Licensing Oportunities

Description

 

Scientists at Leiden University have developed and produced an electronic device to apply microneedle arrays to the skin. Microneedles are designed to be painless whilst overcoming the natural barrier function of the skin that is located in the outermost layer of the epidermis, the stratum corneum (SC). Ideally, the microneedles penetrate the SC and reach the viable epidermis in order to deliver the injected substance, which will then reach the blood vessels that reside in the dermis through further diffusion.

 

Since no nerve endings reside in the epidermis, this method should results in painless drug delivery (see figure). Recently it was shown that using manual application, piercing the skin was unsuccessful with microneedles equal to or shorter than 300 μm, which was postulated to be caused by the elasticity of the skin that enabled folding of skin around the needles. Therefore, an electronic device was developed that allows the insertion of microneedles into the skin with a fixed predetermined (high) velocity.

 

This device was found to overcome the elasticity of the skin, using 300 μm needles, as its use resulted in more effective and higher consistent application/puncturing. Furthermore, the device also overcomes the interindividual and intraindividual variation of skin elasticity, which is caused by factors such as age and skin region, through the fixed predetermined velocity.

Key benefits

 

Compatible with different microneedle arrays

Efficient and reproducible delivery method

 

Applications

 

To apply microneedle arrays to the skin

 

Patent status

 

For this invention a patent application has been filed.

 

Licensing contact

 

Wouter van Muijden

Leiden University Research & Innovation Services (LURIS)

Poortgebouw Noordvleugel

Rijnsburgerweg 10, 2333 AA Leiden

Tel:  +31(0)71 527 5455

Fax: +31(0)71 527 1764

E-mail: w.van.muijden@luris.leidenuniv.nl

 

 

More LURIS Out Licensing Offers I add this page to your favorites

 

New compound offers attractive therapeutic candidate for autoimmune inflammatory diseases

Leiden University has identified a new adenosine receptor agonist. The innovative technology that led to its design, synthesis and pre-clinical evaluations, is now available for licensing purposes and/or for collaborative therapeutic development in the area of autoimmune inflammatory diseases.

More

 

A new way to increase the numbers of mobilized stem cells

Mobilization of stem cells in individuals is currently used for collecting stem cells which can be used to therapeutically intervene in disease processes in the human body. Since a number of years, cytokine mobilized stem cells have become the primary source of hematopoietic stem cells (HSC) and progenitor cells (HPC) for transplantation in humans.

More

 

Novel compound offers new treatment approach for ovarian cancer

A novel compound against ovarian and other cancers has been isolated from the leaves of an Australian native plant belonging to the family of Compositae. This family is known for its natural products, including sesquiterpene lactones (SLs). To date great interest is shown for the potential of SLs as anticancer agent. Different fractions of the crude plant extract were tested in vitro against ovarian cancer cell lines and other cancer cell lines. Fractions with clear cytotoxic effects were selected and further analysed. A compound could be isolated by 1HNMR, 13CNMR and ESI mass spectrometry.

More

A diagnostic marker for early cancer detection

Early stage diagnostics of cancer is important, because patients who are treated for cancer at an early stage have a higher chance on survival. The found marker has a high specificity and sensitivity and can be included in or developed into DNA methylation kits that are used for non-invasive detection of (pre-symptomatic) cancer such as fecal DNA testing. The found marker has been tested in a collection of samples and the presence of the marker was validated in all tumor tissues.

 More

 
 I back I top I  

                                                                

office@biotechnology-europe.com I website@biotechnology-europe.com I service@biotechnology-europe.com

 


 

Advertising Opportunities on Biotechnology Europe

Sponsorship Opportunities on Biotechnology Europe

About Biotechnology Europe

Post a Job on Biotechnology Europe

Post a Company Profile on Biotechnology Europe

Post a News on Biotechnology Europe

Post an Event on Biotechnology Europe

Post a Product on Biotechnology Europe

Post a Publication on Biotechnology Europe

Post a Technology on Biotechnology Europe

Post a Resume on Biotechnology Europe


 

Biotechnology Europe Your Partner in Bioscience and Business

  Central Internet Platform and Service Company For The Life Sciences in Europe

Imprint I Site map I Privacy Policy I Contact us I About us I Copyright BIOTECHNOLOGY WORLD  All rights reserved